Oncocross to co-develop 'dual-target siRNA' with Curi-Jin and Omics AI
Predicted impact: Low
Co-development agreement for a dual-target siRNA; no deal value or revenue share disclosed.
Oncocross온코크로스
382150 · KOSDAQ · ₩382150 · 온코크로스
₩3,110▲ ₩60 (1.97%)End-of-day · Oct 27, 2026 · End-of-day prices.
Oncocross Signs Three-Way Agreement with April Bio and OmicsAI for Joint New Drug Development
Predicted impact: Low
Three-way joint drug development agreement; no financial terms disclosed.
Also known as: Oncocross / 온코크로스 / 382150 / KRX:382150
Source: KRX statistical information